Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,146,812 shares of the company’s stock after buying an additional 5,565 shares during the quarter. Assenagon Asset Management S.A. owned 3.00% of Tarsus Pharmaceuticals worth $63,499,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its holdings in Tarsus Pharmaceuticals by 13.9% in the second quarter. Rhumbline Advisers now owns 49,660 shares of the company’s stock worth $1,350,000 after acquiring an additional 6,070 shares in the last quarter. Quest Partners LLC purchased a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth approximately $61,000. Federated Hermes Inc. increased its stake in Tarsus Pharmaceuticals by 71.2% during the 2nd quarter. Federated Hermes Inc. now owns 26,483 shares of the company’s stock valued at $720,000 after purchasing an additional 11,018 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $114,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on TARS. The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Trading Up 5.0 %

NASDAQ TARS opened at $46.56 on Thursday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market capitalization of $1.78 billion, a PE ratio of -12.22 and a beta of 1.02. The company has a fifty day moving average of $51.01 and a 200 day moving average of $38.02.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.